Anticancer Peptides advanced
Bortezomib Proteasome Inhibition
Detailed mechanism of boronic acid dipeptide bortezomib inhibiting the 26S proteasome in multiple myeloma. This peptide or oligopeptide is studied for its bi...
By Encyclopeptide Editorial | 1 min read
bortezomib proteasome multiple-myeloma boronic-acid cancer
Mechanism of Action
Bortezomib reversibly inhibits the 20S proteasome beta5 subunit chymotrypsin-like activity through its boronic acid moiety forming a reversible covalent bond with the catalytic threonine.
Proteasome Subunit Inhibition
| Subunit | Activity | Bortezomib Effect |
|---|---|---|
| Beta5 | Chymotrypsin-like | Strong inhibition |
| Beta1 | Caspase-like | Moderate |
| Beta2 | Trypsin-like | Weak |
Clinical Applications
- Multiple myeloma (first-line and relapsed/refractory)
- Mantle cell lymphoma
- AL amyloidosis
Chemical Identity
| Property | Value |
|---|---|
| Name | Bortezomib Proteasome Inhibition |
| Category | Anticancer Peptides |
References
- Encyclopeptide Database. “Bortezomib Proteasome Inhibition” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Bortezomib Proteasome Inhibition with interactive quizzes on Wikipept.
Take a Quiz on Wikipept